LAUSR

4070Background: While trimodal therapy with neoadjuvant carboplatin/paclitaxel (CP) has demonstrated superiority over surgery alone for treatment of locally advanced esophageal cancer (LAEC), its superiority to alternative regimens is yet unproven. Here we directly compare CP against cisplatin/5-FU (CF), the historical standard, as a component of trimodal therapy for LAEC. Methods: Patients receiving trimodal therapy with either CP or CF for LAEC at a single institution from 2002 to 2017 were included in this retrospective study. Clinical data, treatment regimen, and tumor response were obtained from medical records. The primary outcome was pathologic complete response (pCR). Secondary outcomes were overall (OS) and disease–free survival (DFS), calculated from the date of surgery until death (OS & DFS) or first recurrence (DFS only). Primary outcomes were measured with logistic regression; survival was estimated with Kaplan–Meier and Cox Proportional Hazards models. Patient characteristics were compared w...